|
|
Composition
Lamivudine
............................................................150 mg
Zidovudine USP
............................................................300 mg
Nevirapine
............................................................200 mg
Indications
Dectrovir-N is indicated for the treatment of HIV infection, once
patients have been stabilized on the maintenance regimen of
nevirapine 200 mg bd, and have demonstrated adequate tolerability
to nevirapine.
Description
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI)
with activity against Human Immunodeficiency Virus Type 1 (HIV-1).
HIV-2 RT and eukaryotic DNA polymerases (such as human DNA
polymerases alpha, beta, or sigma) are not inhibited by nevirapine.
Nevirapine is, in general, only prescribed after the immune system
has declined and infections have become evident. It is always
taken with at least one other HIV medication such as Retrovir or
Videx. The virus can develop resistance to nevirapine if the drug
is taken alone, although even if used properly, nevirapine is
effective for only a limited time.
Nevirapine binds directly to reverse transcriptase (RT) and blocks
the RNA-dependent and DNA-dependent DNA polymerase activities by
causing a disruption of the enzyme's catalytic site. The activity
of nevirapine does not compete with template or nucleoside
triphosphates.
Side Effects
In controlled clinical trials, the most common Nevirapine side
effect was rash, which in 7.6% of subjects was considered severe.
Increases in the liver enzymes occurred in 5-10% of subjects
compared with 2-5% in controls.
CONTRAINDICATIONS
Nevirapine is contraindicated in patients with clinically
significant hypersensitivity to any of the components contained in
the tablet or the oral suspension.
Drug Interaction
Nevirapine is principally metabolized by the liver via the
cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine is known to be
an inducer of these enzymes. As a result, drugs that are
metabolized by these enzyme systems may have lower than expected
plasma levels when coadministered with nevirapine.
Dosage
Adults: 1 tablet twice daily or as per the physician’s advice.
Presentations
30 tablets
|
|